Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines.
Ontology highlight
ABSTRACT: Childhood cancer survivors are at high risk of developing congestive heart failure (CHF) compared with the general population, and there is a dose-dependent increase in CHF risk by anthracycline dose. The mechanism by which this occurs has not been fully elucidated. Metabolomics, the comprehensive profile of small-molecule metabolites, has the potential to provide insight into the pathogenesis of disease states and discover diagnostic markers for therapeutic targets. We performed echocardiographic testing and blood plasma metabolomic analyses (8 pathways; 354 metabolites) in 150 asymptomatic childhood cancer survivors previously treated with anthracyclines. Median time from cancer diagnosis to study participation was 12.4 years (2.6-37.9 years); 64% were treated for a hematologic malignanc
SUBMITTER: Armenian SH
PROVIDER: S-EPMC4053243 | biostudies-literature | 2014 Jun
REPOSITORIES: biostudies-literature
ACCESS DATA